## The NHLBI-Sponsored Consortium for preclinicAl assEs Therapies (CAESAR)

Circulation Research 116, 572-586

DOI: 10.1161/circresaha.116.305462

**Citation Report** 

#	Article	IF	CITATIONS
1	Treatment of Myocardial Ischemia/Reperfusion Injury by Ischemic and Pharmacological Postconditioning. , 2015, 5, 1123-1145.		68
2	Across-Species Transfer of Protection by Remote Ischemic Preconditioning With Species-Specific Myocardial Signal Transduction by Reperfusion Injury Salvage Kinase and Survival Activating Factor Enhancement Pathways. Circulation Research, 2015, 117, 279-288.	2.0	137
3	Translational research: Sounds intriguing, but can at times be a frustrating endeavor. How can we improve our methodology?. Scandinavian Cardiovascular Journal, 2015, 49, 115-116.	0.4	1
4	CAESAR. Circulation Research, 2015, 116, 554-556.	2.0	12
5	Evolving Therapies for Myocardial Ischemia/Reperfusion Injury. Journal of the American College of Cardiology, 2015, 65, 1454-1471.	1.2	777
6	Comparative Efficacy of Intracoronary Allogeneic Mesenchymal Stem Cells and Cardiosphere-Derived Cells in Swine with Hibernating Myocardium. Circulation Research, 2015, 117, 634-644.	2.0	60
7	Cell Therapy Needs RigorousÂTranslational Studies in LargeÂAnimal Models â^—. Journal of the American College of Cardiology, 2015, 66, 2000-2004.	1.2	32
8	The Fifth Domain of Beta 2 Glycoprotein I Protects from Natural IgM Mediated Cardiac Ischaemia Reperfusion Injury. PLoS ONE, 2016, 11, e0152681.	1.1	4
9	Pain and Laboratory Animals: Publication Practices for Better Data Reproducibility and Better Animal Welfare. PLoS ONE, 2016, 11, e0155001.	1.1	117
10	Hibernating Squirrels. Anesthesiology, 2016, 124, 1215-1217.	1.3	2
11	A critical review on the translational journey of cardioprotective therapies!. International Journal of Cardiology, 2016, 220, 176-184.	0.8	33
12	Ischemia/Reperfusion. , 2016, 7, 113-170.		537
13	Remote Ischemic Preconditioning for Cardiac Surgery. Circulation Research, 2016, 118, 1055-1058.	2.0	8
14	Impact of the Timing of Metoprolol Administration During STEMI on InfarctÂSize and Ventricular Function. Journal of the American College of Cardiology, 2016, 67, 2093-2104.	1.2	84
15	The Coronary Circulation as a Target of Cardioprotection. Circulation Research, 2016, 118, 1643-1658.	2.0	193
16	Comparative Hemodynamic Effects of Contemporary Percutaneous Mechanical Circulatory Support Devices in a Porcine Model of Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2016, 9, 2292-2303.	1.1	29
17	Circulation Research "In This Issue―Anthology. Circulation Research, 2016, 119, .	2.0	0
18	Modelling Cardiac Arrest—Are We There?*. Critical Care Medicine, 2016, 44, 1956-1957.	0.4	3

#	Article	IF	CITATIONS
19	Zofenopril Protects Against Myocardial Ischemia–Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability. Journal of the American Heart Association, 2016, 5, .	1.6	63
20	Unusual anatomical origins of the coronary arteries in C57BL/6 mice. Are they strainâ€specific?. Journal of Anatomy, 2016, 229, 703-709.	0.9	9
21	Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease. Nature Reviews Drug Discovery, 2016, 15, 620-638.	21.5	251
22	Using MRI to predict future adverse cardiac remodelling in a male mouse model of myocardial infarction. IJC Heart and Vasculature, 2016, 11, 29-34.	0.6	4
23	Cyclosporine A in ReperfusedÂMyocardialÂInfarction. Journal of the American College of Cardiology, 2016, 67, 365-374.	1.2	144
24	Preoperative Sildenafil administration in children undergoing cardiac surgery: a randomized controlled preconditioning study. European Journal of Cardio-thoracic Surgery, 2016, 49, 1403-1410.	0.6	6
25	Pre- or post-ischemic bilirubin ditaurate treatment reduces oxidative tissue damage and improves cardiac function. International Journal of Cardiology, 2016, 202, 27-33.	0.8	30
26	Why does pre-clinical success in cardioprotection fail at the bedside?. Cardiovascular Research, 2016, 109, 189-190.	1.8	1
27	Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism. Cardiovascular Research, 2017, 113, cvw246.	1.8	78
28	Brief Myocardial Ischemia Produces Cardiac Troponin I Release and Focal Myocyte Apoptosis in the Absence of Pathological Infarction in Swine. JACC Basic To Translational Science, 2017, 2, 105-114.	1.9	81
29	Parathyroid Hormone–Related Peptide. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 529-537.	1.0	3
30	The Right Ventricle Is Dilated During Resuscitation From Cardiac Arrest Caused by Hypovolemia: A Porcine Ultrasound Study*. Critical Care Medicine, 2017, 45, e963-e970.	0.4	45
31	Enhancing reproducibility: Failures from Reproducibility Initiatives underline core challenges. Biochemical Pharmacology, 2017, 138, 7-18.	2.0	22
32	Cardiosphere-Derived Cells Require Endoglin for Paracrine-Mediated Angiogenesis. Stem Cell Reports, 2017, 8, 1287-1298.	2.3	35
33	Critical Issues for the Translation of Cardioprotection. Circulation Research, 2017, 120, 1477-1486.	2.0	241
34	Early Use of N-acetylcysteine With Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction Reduces Myocardial Infarct Size (the NACIAM Trial [N-acetylcysteine in Acute Myocardial Infarction]). Circulation, 2017, 136, 894-903.	1.6	108
35	Exercise-Induced Cardioprotection and the Therapeutic Potential of RIPC. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 397-403.	1.0	16
36	l'll Have the Rigor, but Hold the Mortis. Circulation Research, 2017, 120, 1852-1854.	2.0	7

#	Article	IF	CITATIONS
37	Cell therapy for cardiac repair: what is needed to move forward?. Nature Reviews Cardiology, 2017, 14, 257-258.	6.1	36
38	PVDOMICS Drive the Pulmonary Hypertension Field Into the Precision Medicine Era. Circulation Research, 2017, 121, 1106-1108.	2.0	О
39	Optimization of large animal MI models; a systematic analysis of control groups from preclinical studies. Scientific Reports, 2017, 7, 14218.	1.6	8
40	New Initiatives to Improve the Rigor and Reproducibility of Articles Published in <i>Circulation Research</i> . Circulation Research, 2017, 121, 472-479.	2.0	29
41	Large Animal Model Efficacy Testing Is Needed Prior to Launch of a Stem Cell Clinical Trial. Circulation Research, 2017, 121, 496-498.	2.0	14
42	Is age a key factor contributing to the disparity between success of neuroprotective strategies in young animals and limited success in elderly stroke patients? Focus on protein homeostasis. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3318-3324.	2.4	29
43	Ischemic Conditioning Attenuates Platelet-Mediated Thrombosis. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 391-396.	1.0	10
44	The impact of irreproducibility and competing protection from P2Y12 antagonists on the discovery of cardioprotective interventions. Basic Research in Cardiology, 2017, 112, 64.	2.5	42
45	Postconditioning with Intralipid emulsion protects against reperfusion injury in post-infarct remodeled rat hearts by activation of ROS-Akt/Erk signaling. Translational Research, 2017, 186, 36-51.e2.	2.2	14
46	False positive results in preclinical research. Therapie, 2017, 72, 411-413.	0.6	1
47	Cardioprotection: Where to from here?. Cardiovascular Drugs and Therapy, 2017, 31, 53-61.	1.3	19
48	Global position paper on cardiovascular regenerative medicine. European Heart Journal, 2017, 38, 2532-2546.	1.0	133
49	Does a Newly Characterized Cell From the Bone Marrow Repair the Heart After Acute Myocardial Infarction?. Circulation Research, 2018, 122, 1036-1038.	2.0	2
50	Post-infarct cardiac injury, protection and repair: roles of non-cardiomyocyte multicellular and acellular components. Science China Life Sciences, 2018, 61, 266-276.	2.3	8
51	Translational Research in Cardiovascular Repair. Circulation Research, 2018, 122, 310-318.	2.0	48
52	Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. , 2018, 186, 73-87.		533
53	Cardioprotection research must leave its comfort zone. European Heart Journal, 2018, 39, 3393-3395.	1.0	47
54	Preclinical Studies of Stem Cell Therapy for Heart Disease. Circulation Research, 2018, 122, 1006-1020.	2.0	104

#	Article	IF	CITATIONS
55	Cardioprotective Exercise and Pharmacologic Interventions as Complementary Antidotes to Cardiovascular Disease. Exercise and Sport Sciences Reviews, 2018, 46, 5-17.	1.6	20
56	STAT3 as a common signal of ischemic conditioning: a lesson on "rigor and reproducibility―in preclinical studies on cardioprotection. Basic Research in Cardiology, 2018, 113, 3.	2.5	61
57	OBSOLETE: Animal Models of Ischemic Heart Disease: From Atherosclerosis and Thrombosis to Myocardial Infarction. , 2018, , .		0
58	Sacubitril/Valsartan Averts AdverseÂPost-Infarction Ventricular RemodelingÂand Preserves SystolicÂFunction in Rabbits. Journal of the American College of Cardiology, 2018, 72, 2342-2356.	1.2	63
59	Angiotensin Receptor-Neprilysin Inhibitors Emerge as Potential Treatment for Acute Myocardial Infarction. Journal of the American College of Cardiology, 2018, 72, 2357-2359.	1.2	4
60	Animal Models of Ischemic Heart Disease: From Atherosclerosis and Thrombosis to Myocardial Infarction. , 2018, , 97-110.		0
61	Effect of Intracoronary Metformin on Myocardial Infarct Size in Swine. Circulation Research, 2018, 123, 986-995.	2.0	28
62	Translation, Translation, Translation. Circulation Research, 2018, 123, 931-933.	2.0	12
64	Aging Is Associated With Impaired Activation of Protein Homeostasisâ€Related Pathways After Cardiac Arrest in Mice. Journal of the American Heart Association, 2018, 7, e009634.	1.6	23
65	Guidelines for experimental models of myocardial ischemia and infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 314, H812-H838.	1.5	372
66	Improving the quality of preclinical research echocardiography: observations, training, and guidelines for measurement. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H58-H70.	1.5	37
67	Meta-Analysis of Cell Therapy Studies in Heart Failure and Acute Myocardial Infarction. Circulation Research, 2018, 123, 301-308.	2.0	74
68	Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Research in Cardiology, 2018, 113, 39.	2.5	311
69	Divergent Effects of PKC (Protein Kinase C) $\hat{I}\pm$ in the Human and Animal Heart?. Circulation Genomic and Precision Medicine, 2018, 11, e002104.	1.6	3
70	Cardioprotective Effects of Sphingosine-1-Phosphate Receptor Immunomodulator FTY720 in a Clinically Relevant Model of Cardioplegic Arrest and Cardiopulmonary Bypass. Frontiers in Pharmacology, 2019, 10, 802.	1.6	8
71	Exosomes Engineered to Express a Cardiomyocyte Binding Peptide Demonstrate Improved Cardiac Retention in Vivo. Scientific Reports, 2019, 9, 10041.	1.6	150
72	Cardioprotection. , 2019, , 75-85.		1
73	Sex is no determinant of cardioprotection by ischemic preconditioning in rats, but ischemic/reperfused tissue mass is for remote ischemic preconditioning. Physiological Reports, 2019, 7, e14146.	0.7	24

#	Article	IF	CITATIONS
74	Inducible cardiac-specific overexpression of cyclooxygenase-2 (COX-2) confers resistance to ischemia/reperfusion injury. Basic Research in Cardiology, 2019, 114, 32.	2.5	13
75	Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion. Expert Review of Cardiovascular Therapy, 2019, 17, 683-697.	0.6	14
76	Cardioprotective mechanism of FTY720 in ischemia reperfusion injury. Journal of Basic and Clinical Physiology and Pharmacology, 2019, 30, .	0.7	8
77	Developing LRP1 Agonists into a Therapeutic Strategy in Acute Myocardial Infarction. International Journal of Molecular Sciences, 2019, 20, 544.	1.8	25
78	Editor's Choice- Pathophysiology and therapy of myocardial ischaemia/reperfusion syndrome. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 443-456.	0.4	42
79	Reduced ambient temperature exacerbates SIRS-induced cardiac autonomic dysregulation and myocardial dysfunction in mice. Basic Research in Cardiology, 2019, 114, 26.	2.5	17
80	Protective cardiac conditioning by an atypical cytokine. Clinical Science, 2019, 133, 933-937.	1.8	6
81	Reproducibility and validation of translational pig model of myocardial infarction by the ischemic preconditioning: Effect on intramyocardial hemorrhage. Archives of Cardiovascular Diseases Supplements, 2019, 11, 216.	0.0	0
83	Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. Cardiovascular Research, 2019, 115, 1117-1130.	1.8	125
84	Stable Extracranial ICA Patency after Mechanical Thrombectomy for Ischemic Stroke Patients with Tandem Occlusions: Major determinant of favorable outcome. Archives of Cardiovascular Diseases Supplements, 2019, 11, 216.	0.0	0
85	Delayed Reperfusion—Coronary Artery Reperfusion Close to Complete Myocardial Necrosis Benefits Remote Myocardium and Is Enhanced by Exercise. Frontiers in Physiology, 2019, 10, 157.	1.3	4
86	CIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform): A multicenter preclinical network for testing reproducibility in cardiovascular interventions. Scientific Reports, 2019, 9, 20290.	1.6	15
87	Preconditioning against renal ischaemia reperfusion injury: the failure to translate to the clinic. Journal of Nephrology, 2019, 32, 539-547.	0.9	12
88	Human Tissue-Engineered Model of Myocardial Ischemia–Reperfusion Injury. Tissue Engineering - Part A, 2019, 25, 711-724.	1.6	42
89	Salvianolic acid B protects against myocardial ischaemia-reperfusion injury in rats via inhibiting high mobility group box 1 protein expression through the PI3K/Akt signalling pathway. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 1527-1539.	1.4	23
90	Effects of the Delta Opioid Receptor Agonist DADLE in a Novel Hypoxia-Reoxygenation Model on Human and Rat-Engineered Heart Tissue: A Pilot Study. Biomolecules, 2020, 10, 1309.	1.8	5
91	Development and Long-Term Follow-Up of an Experimental Model of Myocardial Infarction in Rabbits. Animals, 2020, 10, 1576.	1.0	3
92	Damage-Associated Molecular Patterns in Myocardial Infarction and Heart Transplantation: The Road to Translational Success. Frontiers in Immunology, 2020, 11, 599511.	2.2	60

#	Article	IF	CITATIONS
93	Efficacy of a Novel Mitochondrial-Derived Peptide in a Porcine Model of Myocardial Ischemia/Reperfusion Injury. JACC Basic To Translational Science, 2020, 5, 699-714.	1.9	15
94	Message in a Bottle: Upgrading Cardiac Repair into Rejuvenation. Cells, 2020, 9, 724.	1.8	18
95	The Noncanonical Pathway for In Vivo Nitric Oxide Generation: The Nitrate-Nitrite-Nitric Oxide Pathway. Pharmacological Reviews, 2020, 72, 692-766.	7.1	133
96	Myocardial ischaemia–reperfusion injury and cardioprotection in perspective. Nature Reviews Cardiology, 2020, 17, 773-789.	6.1	569
97	Effect of hyperglycaemia and diabetes on acute myocardial ischaemia–reperfusion injury and cardioprotection by ischaemic conditioning protocols. British Journal of Pharmacology, 2020, 177, 5312-5335.	2.7	68
98	Slicing and Culturing Pig Hearts under Physiological Conditions. Journal of Visualized Experiments, 2020, , .	0.2	9
99	Translation from animal studies of novel pharmacological therapies to clinical trials in cardiac arrest: A systematic review. Resuscitation, 2021, 158, 258-269.	1.3	10
100	Rapid Lipid Modification of Endothelial Cell Membranes in Cardiac Ischemia/Reperfusion Injury: a Novel Therapeutic Strategy to Reduce Infarct Size. Cardiovascular Drugs and Therapy, 2021, 35, 113-123.	1.3	8
101	Echocardiography-guided percutaneous left ventricular intracavitary injection as a cell delivery approach in infarcted mice. Molecular and Cellular Biochemistry, 2021, 476, 2135-2148.	1.4	5
102	National Preclinical Sepsis Platform: developing a framework for accelerating innovation in Canadian sepsis research. Intensive Care Medicine Experimental, 2021, 9, 14.	0.9	5
103	Combined meta-analysis of preclinical cell therapy studies shows overlapping effect modifiers for multiple diseases. BMJ Open Science, 2021, 5, e100061.	0.8	1
104	Experimental parameters and infarct size in closed chest pig LAD ischemia reperfusion models; lessons learned. BMC Cardiovascular Disorders, 2021, 21, 171.	0.7	6
105	Translational Block in Stroke: A Constructive and "Out-of-the-Box―Reappraisal. Frontiers in Neuroscience, 2021, 15, 652403.	1.4	21
106	CAESAR's legacy: a new era of rigor in preclinical studies of cardioprotection. Basic Research in Cardiology, 2021, 116, 33.	2.5	12
107	Preclinical trial of a MAP4K4 inhibitor to reduce infarct size in the pig: does cardioprotection in human stem cell-derived myocytes predict success in large mammals?. Basic Research in Cardiology, 2021, 116, 34.	2.5	10
108	Combining stem cells in myocardial infarction: The road to superior repair?. Medicinal Research Reviews, 2022, 42, 343-373.	5.0	23
109	Gene therapy knockdown of Hippo signaling induces cardiomyocyte renewal in pigs after myocardial infarction. Science Translational Medicine, 2021, 13, .	5.8	68
110	Single dose of synthetic microRNA-199a or microRNA-149 mimic does not improve cardiac function in a murine model of myocardial infarction. Molecular and Cellular Biochemistry, 2021, 476, 4093-4106.	1.4	3

#	Article	IF	CITATIONS
111	Delayed Echo Enhancement Imaging to Quantify Myocardial Infarct Size. Journal of the American Society of Echocardiography, 2021, 34, 898-909.	1.2	4
112	Preclinical model of type 1 diabetes and myocardial ischemia/reperfusion injury in conscious rabbits—demonstration of cardioprotection with rapamycin. STAR Protocols, 2021, 2, 100772.	0.5	7
113	IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action. Basic Research in Cardiology, 2021, 116, 52.	2.5	73
114	Peoniflorin Preconditioning Protects Against Myocardial Ischemia/Reperfusion Injury Through Inhibiting Myocardial Apoptosis: RISK Pathway Involved. Applied Biochemistry and Biotechnology, 2022, 194, 1149-1165.	1.4	7
115	Diazoxide preserves myocardial function in a swine model of hypothermic cardioplegic arrest and prolonged global ischemia. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, e385-e400.	0.4	8
117	Cardiac mesenchymal cells from failing and nonfailing hearts limit ventricular dilation when administered late after infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 319, H109-H122.	1.5	4
118	Mitochondrial transplantation in humans: "magical―cure or cause for concern?. Journal of Clinical Investigation, 2018, 128, 5191-5194.	3.9	66
119	EphrinA1-Fc attenuates myocardial ischemia/reperfusion injury in mice. PLoS ONE, 2017, 12, e0189307.	1.1	15
120	Mitochondria as a therapeutic target for cardiac ischemia‑reperfusion injury (Review). International Journal of Molecular Medicine, 2020, 47, 485-499.	1.8	68
121	Regulation of STAT3 and its role in cardioprotection by conditioning: focus on non-genomic roles targeting mitochondrial function. Basic Research in Cardiology, 2021, 116, 56.	2.5	37
122	Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. Cardiovascular Drugs and Therapy, 2023, 37, 793-806.	1.3	10
123	Preconditioning of the Heart Following Transmyocardial Revascularization. , 2015, , 305-310.		Ο
124	Ischemic Tolerance in Uremic Rabbits. World Journal of Cardiovascular Diseases, 2015, 05, 351-360.	0.0	0
125	Diversity of coronary arterial tree in laboratory mice. Folia Morphologica, 2020, 79, 255-264.	0.4	1
128	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2022, 118, 3016-3051.	1.8	30
129	Pathobiology of Myocardial Ischemia and Reperfusion Injury: Models, Modes, Molecular Mechanisms, Modulation, and Clinical Applications. Cardiology in Review, 2023, 31, 252-264.	0.6	9
130	Cardiac cell therapy: a call for action. European Heart Journal, 2022, 43, 2352-2353.	1.0	8
131	No sex-related differences in infarct size, no-reflow, and protection by ischaemic pre-conditioning in G¶ttingen minipigs. Cardiovascular Research, 2023, 119, 561-570.	1.8	18

#	Article	IF	CITATIONS
132	Challenges facing the clinical translation of cardioprotection: 35 years after the discovery of ischemic preconditioning. Vascular Pharmacology, 2022, 144, 106995.	1.0	7
133	Advances in research on the protective mechanisms of traditional Chinese medicine (TCM) in myocardial ischaemia-reperfusion injury. Pharmaceutical Biology, 2022, 60, 931-948.	1.3	1
134	Serum Metabolomics Reveals Distinct Profiles during Ischemia and Reperfusion in a Porcine Model of Myocardial Ischemia–Reperfusion. International Journal of Molecular Sciences, 2022, 23, 6711.	1.8	4
135	Wogonoside preserves against ischemia/reperfusion-induced myocardial injury by suppression of apoptosis, inflammation, and fibrosis <i>via</i> modulating Nrf2/HO-1 pathway. Immunopharmacology and Immunotoxicology, 2022, 44, 877-885.	1.1	1
136	Editorial: New Strategies to Inhibit Cell Death in Myocardial Ischemia-Reperfusion Injury: How to Succeed?. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
137	Preclinical multi-target strategies for myocardial ischemia-reperfusion injury. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	11
138	Mitochondrial calcium and reactive oxygen species in cardiovascular disease. Cardiovascular Research, 2023, 119, 1105-1116.	1.8	16
139	Casdermin D-mediated pyroptosis in myocardial ischemia and reperfusion injury: Cumulative evidence for future cardioprotective strategies. Acta Pharmaceutica Sinica B, 2023, 13, 29-53.	5.7	12
140	PU.1 inhibition does not attenuate cardiac function deterioration or fibrosis in a murine model of myocardial infarction. Molecular and Cellular Biochemistry, 0, , .	1.4	0
141	Acoustic Detection of Retained Perfluoropropane Droplets Within the Developing Myocardial Infarct Zone. Ultrasound in Medicine and Biology, 2022, 48, 2322-2334.	0.7	1
142	New insights into cardioprotection, gained by adopting the CAESAR standards of rigor. Basic Research in Cardiology, 2022, 117, .	2.5	2
143	Remote ischemic conditioning in Ossabaw minipigs induces the release of humoral cardioprotective triggers, but the myocardium does not respond with reduced infarct size. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 323, H1365-H1375.	1.5	11
144	Non-responsiveness to cardioprotection by ischaemic preconditioning in Ossabaw minipigs with genetic predisposition to, but without the phenotype of the metabolic syndrome. Basic Research in Cardiology, 2022, 117, .	2.5	16
145	NLRP3-Inflammasome Inhibition with IZD334 Does Not Reduce Cardiac Damage in a Pig Model of Myocardial Infarction. Biomedicines, 2022, 10, 3056.	1.4	3
146	Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning. Pharmacological Reviews, 2023, 75, 159-216.	7.1	29
147	ATP—Sensitive Potassium Channel Opener Diazoxide Reduces Myocardial Stunning in a Porcine Regional With Subsequent Global Ischemia Model. Journal of the American Heart Association, 2022, 11,	1.6	4
148	Cardioprotective efficacy of limb remote ischaemic preconditioning in rats: discrepancy between a meta-analysis and a three-centre <i>in vivo</i> study. Cardiovascular Research, 2023, 119, 1336-1351.	1.8	4
149	Pathways for Cardioprotection in Perspective: Focus on Remote Conditioning and Extracellular Vesicles. Biology, 2023, 12, 308.	1.3	2

#	Article	IF	CITATIONS
150	A systematic assessment of preclinical multilaboratory studies and a comparison to single laboratory studies. ELife, 0, 12, .	2.8	1
151	Preclinical Large Animal Porcine Models for Cardiac Regeneration and Its Clinical Translation: Role of hiPSC-Derived Cardiomyocytes. Cells, 2023, 12, 1090.	1.8	3
152	Introduction of multicenter design in the non-clinical phase to overcome translational barriers in clinical trials. Translational Medicine, 2023, 10, 52-63.	0.1	0